Abdelrahman Ahmad, Alvarez Enrique
Department of Neurology, Rocky Mountain MS Center at the University of Colorado Anschutz Medical Center, Aurora, CO, USA.
Department of Neurology, Rocky Mountain MS Center at the University of Colorado Anschutz Medical Center, University of Colorado, Aurora, CO, USA.
Neurol Clin. 2024 Feb;42(1):115-135. doi: 10.1016/j.ncl.2023.08.002. Epub 2023 Sep 9.
The treatment of patients with relapsing multiple sclerosis (MS) has advanced tremendously over the past few decades. More efficacious therapies have been approved, which can significantly reduce the inflammatory process of relapsing MS. Neuroprotection by controlling this pathophysiology is important given our current limitations to control progressive MS and induce neurorepair. Here, the authors discuss the current landscape of neurotherapeutics for relapsing MS focusing on newer disease-modifying treatments and their use. Risk mitigation of these medications can greatly improve their safety and improve their benefit-risk balance. The authors discuss treatment strategies for risk mitigation including treatment discontinuation and de-escalation.
在过去几十年中，复发型多发性硬化症（MS）患者的治疗取得了巨大进展。更多有效的疗法已获批准，这些疗法可显著减轻复发型MS的炎症过程。鉴于我们目前在控制进展型MS和诱导神经修复方面存在局限性，通过控制这种病理生理过程来实现神经保护非常重要。在此，作者讨论了复发型MS的神经治疗现状，重点关注新型疾病修正治疗方法及其应用。降低这些药物的风险可极大地提高其安全性，并改善其效益风险平衡。作者讨论了降低风险的治疗策略，包括停药和降阶梯治疗。
